Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03364686 · ClinicalTrials.gov registry record · Phase 2
Transfusion of Biotin-Labeled Red Blood Cells
A Phase 2 study, sponsored by Gladwin, Mark, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03364686 is a Phase 2 study that was terminated before completion, run by Gladwin, Mark, MD. The registered enrollment target is 6 participants.
The verdict
NCT03364686, a Phase 2 study, was terminated before completion, sponsored by Gladwin, Mark, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the impact of genetic and biologic factors in blood donors on red blood cell storage stability after autologous transfusion over the different range of storage period of 5-7 days and 35-42 days in healthy volunteers.
Interventions
- BIOLOGICAL Biotin-Labeled Red Blood Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03364686
The ClinicalTrials.gov registry entry for NCT03364686 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gladwin, Mark, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biotin-Labeled Red Blood Cells is the first listed.
NCT03364686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03364686 about?
NCT03364686 is a clinical study titled "Transfusion of Biotin-Labeled Red Blood Cells". The purpose of this research is to evaluate the impact of genetic and biologic factors in blood donors on red blood cell storage stability after autologous transfusion over the different range of storage period of 5-7 days and 35-42 days in healthy volunteers.
What is the current status of trial NCT03364686?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-09-16. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT03364686?
The interventions under investigation include: Biotin-Labeled Red Blood Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03364686?
This trial is sponsored by Gladwin, Mark, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.